Bottom line
What is ARSRX's expense ratio?
ARSRX's expense ratio is 1.26%, or about $126 a year on every $10,000 invested. That is more expensive than 76% of large blend funds we track (median 0.83%). It has no front-end sales load. Its expense ratio includes a 0.5% 12b-1 marketing fee.
Updated Nov 25, 2025
ARSRX fee table
| Net expense ratio | 1.26% |
|---|---|
| Gross expense ratio | 1.3% |
| Management fee | 0.78% |
| 12b-1 (distribution) fee | 0.5% |
| Other expenses | 0% |
| Acquired fund fees | 0.02% |
| Fee waiver / reimbursement | -0.04% |
| Max front-end sales load | 0% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed Nov 25, 2025
What ARSRX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| ARSRX | $129 | $409 | $710 | $1,564 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.26% expense ratio costs roughly $68,200 in lost growth, versus about $46,700 for the median large blend fund (0.83%).